Huntsville, Ala.,– Transomic Technologies, located on the campus of the HudsonAlpha Institute for Biotechnology, has announced that their CRISPR whole genome arrayed library has been placed at the California NanoSystem Institute at UCLA’s Molecular Screening Shared Resource (MSSR) technology center. Through this arrangement, Transomic Technologies will provide the UCLA research community with access to the latest in genomic tools. Use of Transomic’s CRISPR library will be overseen by Dr. Robert Damoiseaux, director of the MSSR.
“Transomic’s CRISPR library is an important and exciting asset to the UCLA research community,” said Dr. Damoiseaux. “Complementary to the existing genomic tools at the MSSR, this CRISPR library will enable UCLA researchers to increase their ability to perform functional genomics screens, greatly enhancing their research capacity for drug discovery and basic research.”
“Our transEDIT-dual CRISPR arrayed library is built around the incredible power of the CRISPR-Cas9 gene-editing technology, “said Blake Simmons, CEO of Transomic Technologies. “This is one of the many tools we offer life science researchers enabling them to make discoveries that ultimately lead to a healthier generation.”
These CRISPR genome-editing tools and other gene modulation tools can be purchased through Transomic Technologies at www.transomic.com.
About transOMIC: transOMIC technologies provides innovative tools and strategies for life science research to help unravel genetic complexity and understand disease development. This mission, coupled with a good understanding of the tools that life science researchers need, drives our focus to be a research partner; delivering technologies in a cost-effective and technically supported manner to enable discovery across the genome. We have an extensive offering of gene-based products to enable research scientists to perform genome editing, gene knockdown, and gene over-expression studies. These types of studies produce insights into gene function which ultimately provide biological understanding of disease and possibilities for therapies. Our leading-edge products are developed through ongoing collaborations with academic thought leaders.
